Patents Examined by Jacob Cheu
  • Patent number: 9958459
    Abstract: Provided herein are protein biomarkers for NETosis related diseases, including proteases. Also provided are substrate sequences of such proteases and uses thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 1, 2018
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Ye Jin, Terry Hermiston, John Murphy
  • Patent number: 9945853
    Abstract: The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 17, 2018
    Assignees: Université Laval, Hérma-Québec, University of Washington
    Inventors: Eric Boilard, Luc Boudreau, Louis Thibault, Michael Herman Gelb
  • Patent number: 9879091
    Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: January 30, 2018
    Assignee: ASTUTE MEDICAL, INC.
    Inventors: Ravi A. Vijayendran, Srivatsa Venkatasubbarao
  • Patent number: 9874573
    Abstract: Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: January 23, 2018
    Inventor: Sarka O. Southern
  • Patent number: 9856315
    Abstract: The disclosure features over 5000 methylation and acetylation sites identified in human cell line, human serum and mouse tissues, peptides (including AQUA peptides) comprising a methylation or acetylation site of the disclosure, antibodies specifically bind to a methylation or acetylation site of the disclosure, and diagnostic and therapeutic uses of the above.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 2, 2018
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Hongbo Gu, Ailan Guo, Daniel Mulhern, Jeffrey C. Silva, Jing Zhou
  • Patent number: 9857386
    Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 2, 2018
    Assignee: ZORA BIOSCIENCES OY
    Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
  • Patent number: 9850515
    Abstract: The present invention provides methods of detecting a target molecule in a sample comprising incubating the sample with two or more detectably labeled probes, partitioning the sample into multiple partitions, and detecting the presence of the two or more probes in the same partition.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 26, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Adam M. McCoy, Svilen Tzonev, Frank Hsiung
  • Patent number: 9835632
    Abstract: The present invention provides methods for predicting the likelihood of mucosal healing in an individual with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis (UC). In addition, the present invention provides methods for monitoring the progression of mucosal healing in an individual with a disease such as IBD. Information on mucosal healing status derived from the use of the present invention can also aid in optimizing therapy and/or monitoring the therapeutic efficiency of an anti-TNF? inhibitor drug.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: December 5, 2017
    Assignee: Nestec S.A.
    Inventors: Sharat Singh, Severine Vermeire
  • Patent number: 9835631
    Abstract: Provided herein is a sandwich immunoassay for detecting cross-linked PIIINP that has at least two strands of PIIINP joined together by inter-strand cross-linking each having a C-terminal neo-epitope of PIIINP that is generated by N-protease cleavage of intact type III procollagen. A biological sample having the cross-linked PIIINP is contacted with a first surface-bound monoclonal antibody and then by a second monoclonal antibody, both specifically reactive with a neoepitope in the C-terminal sequence of PIIINP, and then binding of the second monoclonal antibody is determined. Also provided is a method for evaluating the efficacy of an antagonist drug targeting lysyl oxidases via the immunoassay and a kit containing a solid support binding the first monoclonal antibody and containing the second monoclonal antibody.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: December 5, 2017
    Assignee: Nordic Bioscience A/S
    Inventors: Federica Genovese, Mette Juul Nielsen, Lise Larsen, Diana Julie Oersnes-Leeming, Morten Karsdal
  • Patent number: 9816999
    Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: November 14, 2017
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Patent number: 9810670
    Abstract: The present invention provides methods for analyzing compositions of polypeptides such as antibodies by ionic strength-mediated pH gradient ion exchange chromatography. In some aspects, the methods use a combination of pH gradients and ionic strength gradients to separate the polypeptide from charge variants of the polypeptide. In some aspects, the methods use a stable ionic strength to optimize the pH gradient separation window to separate the polypeptide from charge variants. Such methods are useful for analyzing polypeptide, e.g. antibodies, with a pI greater than 9 or a pI less than 7. In some aspects, the invention provides a multiproduct method for the analysis of polypeptides of varying pI's.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: November 7, 2017
    Assignee: GENENTECH, INC.
    Inventors: Yajun Wang, George Tony Moreno, Boyan Zhang, Liangyi Zhang, Dell Farnan, Thomas Patapoff
  • Patent number: 9810694
    Abstract: The present invention is drawn to methods for detection of the fully human antibodies infiltrated into a solid tissue, and to optimize methods for generating, selecting, and expanding monoclonal antibodies to large numbers for antibody-based therapy and diagnosis. The invention is exemplified in a number of implementations and applications, some of which are summarized below and throughout the specification. In one aspect, the invention is directed to methods for identifying potentially therapeutic fully human antibodies that have infiltrated a solid tissue comprising the following steps: (a) detecting and sorting into one or more subsets a sample of antibodies from an accessible tissue of an individual; (b) characterization of the fully human antibodies; (c) production and purification of the fully human antibody; (d) assessment of the therapeutic and diagnostic activity of fully human antibody.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: November 7, 2017
    Inventors: Gennady Bratslavsky, Ilya Tsimafeyeu
  • Patent number: 9804166
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 31, 2017
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Patent number: 9804165
    Abstract: The present invention includes methods for detecting benign to malignant transformation of a cancer in a subject, comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretically separated ENOX2 transcript variants with an ENOX2 electron donor; and detecting the presence of the one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of one or more activated ENOX2 transcript variants in the sample is indicative of the malignant transformation of the cancer, whereby a 10 to 100 fold increase in detection sensitivity is obtained for the one or more activated ENOX2 transcript variants when compared to an equivalent non-activated ENOX2 transcript variant.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 31, 2017
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventor: D. James Morre
  • Patent number: 9797838
    Abstract: This present invention relates to a screening method for rapidly identifying the hybridomas upon cell size and the expression of an exogenous label such as fluorescence labeling. This method of this present invention can largely shortens the time cost for antibody development by saving the time period with comparison of traditional methods using cell culture with media such as HAT medium.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 24, 2017
    Assignee: TUNGHAI UNIVERSITY
    Inventors: Chang-Chi Hsieh, Ming-Shiou Jan, Ai Shih, Chuan-Kai Chou, Yen-Wan Hsiao, Ying-Chun Lai
  • Patent number: 9797910
    Abstract: The present invention relates to an assay for determining endogenous levels of analyte in vivo. In particular, the present invention is directed to an assay for determining endogenous levels of stromal cell-derived factor (SDF-1) isoforms in vivo.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: October 24, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Weixun Wang, Bernard Karsten Choi, Lucinda H. Cohen
  • Patent number: 9791436
    Abstract: A biosensor molecule comprises: a protease amino acid sequence; at least one sensor comprising at least one sensor amino acid sequence which is responsive to at least one target molecule; and an inhibitor of the protease activity of said protease amino acid sequence; wherein the biosensor is switchable from a protease active to a protease inactive state, or from a protease inactive to a protease active state when said sensor responds to said target molecule. The biosensor protease may be a protease of a virus such as a Potyvirus or a Flavivirus wherein the inhibitor is an autoinhibitory peptide derived from the virus. The biosensor may respond to the target molecule allosterically or may be cleaved by a target protease molecule.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 17, 2017
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Kirill Alexandrov, Viktor Stein, Matt Trau
  • Patent number: 9784739
    Abstract: Compositions and methods for diagnosing an increased risk of NPSLE are provided.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 10, 2017
    Assignee: The Research Foundation for State University of New York
    Inventors: Henri Tiedge, Anna Iacoangeli
  • Patent number: 9784749
    Abstract: The present invention relates generally to assays, methods and kits for the prognosis and/or diagnosis of cardiac disorders. The present invention also provides, for example, binding agents to a novel class of circulating cardiac troponin T upstream open reading frame (TnTuORF) peptide biomarkers for use in predicting or diagnosing a cardiac disorder other than myocardial infarction or unstable angina. In addition, the binding agents of the present invention may be used to enhance the sensitivity and false positive performance of cardiac troponins in the prognosis and diagnosis of myocardial infarction.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: October 10, 2017
    Assignee: Otago Innovation Limited
    Inventors: Jacqueline Amanda Lee, Christopher Joseph Pemberton
  • Patent number: 9777338
    Abstract: The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 3, 2017
    Assignee: MESO SCALE TECHNOLOGIES, LLC.
    Inventors: Eli N. Glezer, George Sigal